Finding 574543 (2023-003)

Material Weakness
Requirement
AB
Questioned Costs
$1
Year
2023
Accepted
2025-08-22
Audit: 364802

AI Summary

  • Core Issue: Salary expenses charged to federal grants exceeded the NIH salary cap due to incorrect calculations.
  • Impacted Requirements: Compliance with Sections 200.303 and 200.430 of the Uniform Guidance regarding internal controls and allowable costs.
  • Recommended Follow-Up: Implement stronger internal controls to ensure accurate salary cap calculations for grant-related payroll expenses.

Finding Text

Finding 2023-003 – Activities Allowed or Unallowed and Allowable Costs/Cost PrinciplesInformation of the federal program:Federal Grantor: United States Department of Health and Human ServicesAssistance Listing No.: 93.866, Aging ResearchFederal Grantor: United States Department of Health and Human Services (HHS)Assistance Listing No.: 93.837, Cardiovascular Diseases ResearchPass-Through Grantor: University of Wisconsin – MadisonCriteria or specific requirement (including statutory, regulatory or other citation):Section 200.303 of the Uniform Guidance states the following regarding internal control: “The non-Federal entity must: (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”Section 200.430 states the following: (d) Unallowable costs. (1) Costs which are unallowable under other sections of these principles must not be allowable under this section solely on the basis that they constitute personnel compensation.(2) The NIH allowable compensation for certain employees is subject to a ceiling in accordance with statute. For the amount of the ceiling for cost-reimbursement contracts, the covered compensation subject to the ceiling, the covered employees, and other relevant provisions, see 10 U.S.C. 2324(e)(1)(P), and 41 U.S.C. 1127 and 4304(a)(16). For other types of Federal awards, other statutory ceilings may apply.Condition:The salary expense recorded for employees above the NIH salary cap was not calculated correctly as it did not properly take into consideration the NIH salary cap requirements.Cause:Management did not calculate the NIH salary cap requirement correctly; therefore, the allowable payroll expense reported was overstated.Effect or potential effect:Payroll expenditures exceeding the NIH salary cap were charged to the research and development grants.Questioned costs:$819 related to the following federal awards:93.86693.837Context:We selected 40 payroll transactions which totaled $32,051 from a population of $5,471,507 related payroll costs for the year ended December 31, 2023. We identified 4 instances, which represented total salary cost of $2,337, where the salary cap amounts were not calculated correctly and, therefore, the salary expense charged to the grants was overstated by $819.Identification as a repeat finding, if applicable:This finding is not a repeat finding from the prior year.Recommendation:Management should implement internal controls to review the salary cap adjustment calculation to ensure that the salary expenses charged to the program are appropriate.Views of responsible officials:The Research Institute has had a long-standing practice of reviewing salary cap limitations on grants. During the initial meeting for a new award (“The Kick-Off meeting”), the level of effort for proposed staff is confirmed, and any staff salaries exceeding the current salary cap were identified. This ensured that appointments on grants were appropriately updated. Due to changes in the GM10 not under the purview of the Research Institute select effort distributions were inadvertently changed to accommodate salary changes.

Corrective Action Plan

Finding 2023-003 – Activities Allowed or Unallowed and Allowable Costs/Cost Principles Assistance Listing Multiple Workday allows costing allocations, which automatically split salaries above and below the cap. This process ensures that only appropriate salaries are charged to the grant. Management will update the salary cap in the system in a timely manner and validate that the system is calculating correctly. Going forward, management will do a quarterly review of the effort distributions, and make adjustments when needed in a timely manner. Responsible Official: Robert Stanton, Assistant Vice President, Research and Financial Operations, NSH Research Central Office

Categories

Questioned Costs Allowable Costs / Cost Principles Matching / Level of Effort / Earmarking

Other Findings in this Audit

  • 574483 2023-001
    Material Weakness
  • 574484 2023-002
    Material Weakness
  • 574485 2023-001
    Material Weakness
  • 574486 2023-002
    Material Weakness
  • 574487 2023-001
    Material Weakness
  • 574488 2023-005
    Significant Deficiency
  • 574489 2023-001
    Material Weakness
  • 574490 2023-005
    Significant Deficiency
  • 574491 2023-001
    Material Weakness
  • 574492 2023-002
    Material Weakness
  • 574493 2023-005
    Significant Deficiency
  • 574494 2023-005
    Significant Deficiency
  • 574495 2023-001
    Material Weakness
  • 574496 2023-005
    Significant Deficiency
  • 574497 2023-001
    Material Weakness
  • 574498 2023-001
    Material Weakness
  • 574499 2023-002
    Material Weakness
  • 574500 2023-005
    Significant Deficiency
  • 574501 2023-001
    Material Weakness
  • 574502 2023-002
    Material Weakness
  • 574503 2023-005
    Significant Deficiency
  • 574504 2023-005
    Significant Deficiency
  • 574505 2023-001
    Material Weakness
  • 574506 2023-001
    Material Weakness
  • 574507 2023-005
    Significant Deficiency
  • 574508 2023-001
    Material Weakness
  • 574509 2023-002
    Material Weakness
  • 574510 2023-004
    Material Weakness
  • 574511 2023-001
    Material Weakness
  • 574512 2023-001
    Material Weakness
  • 574513 2023-005
    Significant Deficiency
  • 574514 2023-001
    Material Weakness
  • 574515 2023-005
    Significant Deficiency
  • 574516 2023-001
    Material Weakness
  • 574517 2023-005
    Significant Deficiency
  • 574518 2023-001
    Material Weakness
  • 574519 2023-005
    Significant Deficiency
  • 574520 2023-001
    Material Weakness
  • 574521 2023-005
    Significant Deficiency
  • 574522 2023-001
    Material Weakness
  • 574523 2023-005
    Significant Deficiency
  • 574524 2023-001
    Material Weakness
  • 574525 2023-005
    Significant Deficiency
  • 574526 2023-001
    Material Weakness
  • 574527 2023-005
    Significant Deficiency
  • 574528 2023-001
    Material Weakness
  • 574529 2023-005
    Significant Deficiency
  • 574530 2023-001
    Material Weakness
  • 574531 2023-005
    Significant Deficiency
  • 574532 2023-001
    Material Weakness
  • 574533 2023-005
    Significant Deficiency
  • 574534 2023-001
    Material Weakness
  • 574535 2023-005
    Significant Deficiency
  • 574536 2023-001
    Material Weakness
  • 574537 2023-001
    Material Weakness
  • 574538 2023-001
    Material Weakness
  • 574539 2023-001
    Material Weakness
  • 574540 2023-001
    Material Weakness
  • 574541 2023-001
    Material Weakness
  • 574542 2023-002
    Material Weakness
  • 574544 2023-002
    Material Weakness
  • 574545 2023-001
    Material Weakness
  • 574546 2023-001
    Material Weakness
  • 574547 2023-005
    Significant Deficiency
  • 574548 2023-001
    Material Weakness
  • 574549 2023-005
    Significant Deficiency
  • 574550 2023-001
    Material Weakness
  • 574551 2023-005
    Significant Deficiency
  • 574552 2023-001
    Material Weakness
  • 574553 2023-002
    Material Weakness
  • 574554 2023-005
    Significant Deficiency
  • 574555 2023-001
    Material Weakness
  • 574556 2023-005
    Significant Deficiency
  • 574557 2023-001
    Material Weakness
  • 574558 2023-005
    Significant Deficiency
  • 574559 2023-001
    Material Weakness
  • 574560 2023-002
    Material Weakness
  • 574561 2023-001
    Material Weakness
  • 574562 2023-002
    Material Weakness
  • 574563 2023-001
    Material Weakness
  • 574564 2023-005
    Significant Deficiency
  • 574565 2023-002
    Material Weakness
  • 574566 2023-001
    Material Weakness
  • 574567 2023-002
    Material Weakness
  • 574568 2023-001
    Material Weakness
  • 574569 2023-001
    Material Weakness
  • 574570 2023-001
    Material Weakness
  • 574571 2023-005
    Significant Deficiency
  • 574572 2023-001
    Material Weakness
  • 574573 2023-001
    Material Weakness
  • 574574 2023-003
    Material Weakness
  • 574575 2023-001
    Material Weakness
  • 574576 2023-002
    Material Weakness
  • 574577 2023-005
    Significant Deficiency
  • 574578 2023-001
    Material Weakness
  • 574579 2023-002
    Material Weakness
  • 574580 2023-005
    Significant Deficiency
  • 574581 2023-001
    Material Weakness
  • 574582 2023-006
    Material Weakness
  • 574583 2023-001
    Material Weakness
  • 574584 2023-006
    Material Weakness
  • 1150925 2023-001
    Material Weakness
  • 1150926 2023-002
    Material Weakness
  • 1150927 2023-001
    Material Weakness
  • 1150928 2023-002
    Material Weakness
  • 1150929 2023-001
    Material Weakness
  • 1150930 2023-005
    Significant Deficiency
  • 1150931 2023-001
    Material Weakness
  • 1150932 2023-005
    Significant Deficiency
  • 1150933 2023-001
    Material Weakness
  • 1150934 2023-002
    Material Weakness
  • 1150935 2023-005
    Significant Deficiency
  • 1150936 2023-005
    Significant Deficiency
  • 1150937 2023-001
    Material Weakness
  • 1150938 2023-005
    Significant Deficiency
  • 1150939 2023-001
    Material Weakness
  • 1150940 2023-001
    Material Weakness
  • 1150941 2023-002
    Material Weakness
  • 1150942 2023-005
    Significant Deficiency
  • 1150943 2023-001
    Material Weakness
  • 1150944 2023-002
    Material Weakness
  • 1150945 2023-005
    Significant Deficiency
  • 1150946 2023-005
    Significant Deficiency
  • 1150947 2023-001
    Material Weakness
  • 1150948 2023-001
    Material Weakness
  • 1150949 2023-005
    Significant Deficiency
  • 1150950 2023-001
    Material Weakness
  • 1150951 2023-002
    Material Weakness
  • 1150952 2023-004
    Material Weakness
  • 1150953 2023-001
    Material Weakness
  • 1150954 2023-001
    Material Weakness
  • 1150955 2023-005
    Significant Deficiency
  • 1150956 2023-001
    Material Weakness
  • 1150957 2023-005
    Significant Deficiency
  • 1150958 2023-001
    Material Weakness
  • 1150959 2023-005
    Significant Deficiency
  • 1150960 2023-001
    Material Weakness
  • 1150961 2023-005
    Significant Deficiency
  • 1150962 2023-001
    Material Weakness
  • 1150963 2023-005
    Significant Deficiency
  • 1150964 2023-001
    Material Weakness
  • 1150965 2023-005
    Significant Deficiency
  • 1150966 2023-001
    Material Weakness
  • 1150967 2023-005
    Significant Deficiency
  • 1150968 2023-001
    Material Weakness
  • 1150969 2023-005
    Significant Deficiency
  • 1150970 2023-001
    Material Weakness
  • 1150971 2023-005
    Significant Deficiency
  • 1150972 2023-001
    Material Weakness
  • 1150973 2023-005
    Significant Deficiency
  • 1150974 2023-001
    Material Weakness
  • 1150975 2023-005
    Significant Deficiency
  • 1150976 2023-001
    Material Weakness
  • 1150977 2023-005
    Significant Deficiency
  • 1150978 2023-001
    Material Weakness
  • 1150979 2023-001
    Material Weakness
  • 1150980 2023-001
    Material Weakness
  • 1150981 2023-001
    Material Weakness
  • 1150982 2023-001
    Material Weakness
  • 1150983 2023-001
    Material Weakness
  • 1150984 2023-002
    Material Weakness
  • 1150985 2023-003
    Material Weakness
  • 1150986 2023-002
    Material Weakness
  • 1150987 2023-001
    Material Weakness
  • 1150988 2023-001
    Material Weakness
  • 1150989 2023-005
    Significant Deficiency
  • 1150990 2023-001
    Material Weakness
  • 1150991 2023-005
    Significant Deficiency
  • 1150992 2023-001
    Material Weakness
  • 1150993 2023-005
    Significant Deficiency
  • 1150994 2023-001
    Material Weakness
  • 1150995 2023-002
    Material Weakness
  • 1150996 2023-005
    Significant Deficiency
  • 1150997 2023-001
    Material Weakness
  • 1150998 2023-005
    Significant Deficiency
  • 1150999 2023-001
    Material Weakness
  • 1151000 2023-005
    Significant Deficiency
  • 1151001 2023-001
    Material Weakness
  • 1151002 2023-002
    Material Weakness
  • 1151003 2023-001
    Material Weakness
  • 1151004 2023-002
    Material Weakness
  • 1151005 2023-001
    Material Weakness
  • 1151006 2023-005
    Significant Deficiency
  • 1151007 2023-002
    Material Weakness
  • 1151008 2023-001
    Material Weakness
  • 1151009 2023-002
    Material Weakness
  • 1151010 2023-001
    Material Weakness
  • 1151011 2023-001
    Material Weakness
  • 1151012 2023-001
    Material Weakness
  • 1151013 2023-005
    Significant Deficiency
  • 1151014 2023-001
    Material Weakness
  • 1151015 2023-001
    Material Weakness
  • 1151016 2023-003
    Material Weakness
  • 1151017 2023-001
    Material Weakness
  • 1151018 2023-002
    Material Weakness
  • 1151019 2023-005
    Significant Deficiency
  • 1151020 2023-001
    Material Weakness
  • 1151021 2023-002
    Material Weakness
  • 1151022 2023-005
    Significant Deficiency
  • 1151023 2023-001
    Material Weakness
  • 1151024 2023-006
    Material Weakness
  • 1151025 2023-001
    Material Weakness
  • 1151026 2023-006
    Material Weakness

Programs in Audit

ALN Program Name Expenditures
21.027 Coronavirus State and Local Fiscal Recovery Funds $1.40M
93.391 Covid-19 Activities to Support State, Tribal, Local and Territorial (stlt) Health Department Response to Public Health Or Healthcare Crisis $1.26M
93.394 Cancer Detection and Diagnosis Research $816,528
21.027 Covid-19 Coronavirus State and Local Fiscal Recovery Funds $609,195
93.310 Trans-Nih Research Support $313,490
93.889 National Bioterrorism Hospital Preparedness Program $270,452
16.560 National Institute of Justice Research, Evaluation, and Development Project Grants $187,525
93.323 Covid-19 Epidemiology and Laboratory Capacity for Infectious Diseases (elc) $167,045
93.350 National Center for Advancing Translational Sciences $164,703
93.994 Maternal and Child Health Services Block Grant to the States $119,852
93.368 21st Century Cures Act - Precision Medicine Initiative $94,609
93.838 Lung Diseases Research $93,061
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $80,571
93.855 Allergy and Infectious Diseases Research $72,630
93.351 Research Infrastructure Programs $67,407
93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health $64,097
93.396 Cancer Biology Research $56,813
12.420 Military Medical Research and Development $55,493
93.226 Research on Healthcare Costs, Quality and Outcomes $36,564
93.865 Child Health and Human Development Extramural Research $29,653
93.393 Cancer Cause and Prevention Research $17,681
93.307 Minority Health and Health Disparities Research $15,122
93.172 Human Genome Research $15,121
93.397 Cancer Centers Support Grants $14,078
93.866 Aging Research $11,855
93.273 Alcohol Research Programs $10,732
14.218 Community Development Block Grants/entitlement Grants $10,044
93.837 Cardiovascular Diseases Research $8,921
93.361 Nursing Research $7,645
93.667 Social Services Block Grant $7,551
93.839 Blood Diseases and Resources Research $3,217
93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders $597
93.395 Cancer Treatment Research $512
93.946 Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs $-697
93.859 Biomedical Research and Research Training $-2,184
93.242 Mental Health Research Grants $-20,481